They are Canadian suppliers but they can compete internationally. This is a global system, so they can sell the technologies wherever they would fit the market needs.
The advantage of a technology like the cyclotron, for instance, is that it is localized. As opposed to being a big reactor that produces a large volume of medical isotopes, these are smaller machines that are sitting in universities or S and T campuses or close to hospitals and really can provide medical isotopes on a regional basis. We have examples from our Canadian proponents who have successfully been producing a volume that could supply a large urban area such as Vancouver. TRIUMF had an announcement on this scale recently. The University of Alberta and the university in Sherbrooke in February, announced that the quality of medical isotopes produced is of the same purity as what we would find on the market, and linear accelerators also demonstrated they can produce volumes comparable to what is in the market, so they are making progress toward being able to compete in 2016.
On your specific question about market share, we cannot predetermine at this point in time what that would be.